Stryker Co. (NYSE:SYK) Shares Bought by Stifel Financial Corp

Stifel Financial Corp increased its position in Stryker Co. (NYSE:SYK - Free Report) by 2.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 610,336 shares of the medical technology company's stock after acquiring an additional 14,927 shares during the quarter. Stifel Financial Corp owned about 0.16% of Stryker worth $219,760,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kohmann Bosshard Financial Services LLC bought a new stake in Stryker during the 4th quarter valued at approximately $25,000. Rakuten Securities Inc. raised its position in shares of Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after buying an additional 68 shares during the last quarter. Centricity Wealth Management LLC purchased a new position in shares of Stryker in the fourth quarter worth $30,000. BankPlus Trust Department bought a new position in shares of Stryker during the fourth quarter worth $33,000. Finally, VSM Wealth Advisory LLC purchased a new position in Stryker during the fourth quarter valued at $36,000. Institutional investors own 77.09% of the company's stock.

Analyst Ratings Changes

SYK has been the subject of several research analyst reports. Royal Bank of Canada raised their price target on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a report on Wednesday, January 29th. Needham & Company LLC reissued a "buy" rating and issued a $442.00 price objective on shares of Stryker in a research report on Friday, March 21st. Barclays lifted their target price on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Wells Fargo & Company increased their price objective on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Finally, Stifel Nicolaus raised their price target on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research note on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, Stryker presently has an average rating of "Moderate Buy" and an average price target of $423.53.

Stryker Price Performance

Shares of SYK stock traded up $3.83 during mid-day trading on Thursday, hitting $360.94. 1,349,722 shares of the stock were exchanged, compared to its average volume of 1,356,479. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a market cap of $137.77 billion, a PE ratio of 46.51, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. The firm has a fifty day moving average of $368.69 and a 200 day moving average of $372.95.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the business earned $3.46 earnings per share. Research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.93%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's payout ratio is 43.30%.

Insider Transactions at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.20% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.